Keywords
central nervous system neoplasms
classification
signal transduction
biomarkers
How to Cite
Abstract
Glioblastoma Multiforme (GBM) is the most frequent primary malignant neoplasm of the Central Nervous System (CNS) worldwide. It has one of the lowest survival rates of any brain tumor despite advances in diagnostic techniques, greater understanding of its tumor genesis and the existence of targeted therapies. The 2016 World Health Organization (WHO) CNS Tumor Classification is modified due to the relevance of including molecular parameters in addition to the classic histological characterization for diagnosis, the main altered signaling pathways and the methyl-guanine methyl transferase (MGMT) biomarker.
This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The authors keep the copyright and publication rights in the journal the right of the first publication and this possibility to edit, reproduce, distribute, expose and publicly communicate on the magazine's website. Likewise, it assumes the commitment on any litigation or claim related to the rights of intellectual property, exonerating of responsibility to the Science and Health Magazine of the UCIMED. In addition, you can see how they are published in this journal (eg, Include in an institutional repository or publish it in a book) as long as they clearly indicate the work published for the first time in the magazine Science and Health of the UCIMED.